Trevigen has announced a validated assay with high sensitivity and pre-coated antibody plates to measure the effectiveness of PARP inhibitors in cell and tissue lysates.
In anti-cancer drug development, a current molecular target of high interest is poly(ADP-ribose) polymerase (PARP), as it is intimately involved in DNA repair and the survival or death of cancer cells.
Until now, measuring the effectiveness of PARP inhibitors in cell and tissue lysates has been difficult and time consuming due to a lack of refined immunological reagents in an optimised and quantitative assay.
Trevigen addresses this problem with the release of the HT PARP in vivo Pharmacodynamic Assay II, which is a high-throughput, Chemiluminescent, Par Elisa assay kit that has been validated on human peripheral blood lymphocytes and also shown to work with normal and tumour tissue.
This improved assay features: pre-coated capture antibody plates; broad linear dynamic range to 1,000pg/ml; high signal-to-noise ratio; and detection sensitivity of 2pg/ml of PAR.
The amount of PAR present correlates directly with the activity of the PARP enzyme in cell lysates.
This assay is suitable for quantification of PAR in peripheral blood mononuclear cells, tissues and cultured cells.
